APM
CNTA

Avidity Partners Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Avidity Partners Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-529,000
Closed -$7.61M – 65
2025
Q1 		$7.61M Sell
529,000
-636,800
-55% -$10.4M 1.45% 27
2024
Q4 		$19.5M Sell
1,165,800
-966,200
-45% -$16M 1.92% 22
2024
Q3 		$34.1M Buy
+2,132,000
New +$26.1M 1.74% 23

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Avidity Partners Management's CNTA Position: Q2 2025 in Review

Avidity Partners Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2025, closing a stake of 529,000 shares — an estimated $7.61M sold.

Avidity Partners Management first reported a position in CNTA in Q3 2024 and held it in 3 quarters. The position peaked at $34.1M in Q3 2024. 117 funds tracked by Wall St. Rank hold CNTA as of Q2 2025.

  • Avidity Partners Management reported no remaining Centessa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Avidity Partners Management sold 529,000 Centessa Pharmaceuticals shares in Q2 2025, an estimated $7.61M.
  • Avidity Partners Management first reported a position in Centessa Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Avidity Partners Management's Centessa Pharmaceuticals position peaked at $34.1M in Q3 2024.
  • 117 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2025.

Based on Avidity Partners Management's 13F filing for Q2 2025, filed 14 Aug 2025.